Covid-19: FDA approves use of convalescent plasma to treat critically ill patients

The US Food and Drug Administration has approved the use of plasma from recovered patients to treat people who are critically ill with covid-19, provided that doctors get approval over the telephone.1 The method has been used in the past to treat diseases such as polio, measles, and mumps, in the 1918 flu epidemic, and in previous outbreaks of respiratory infections similar to covid-19. The FDA’s decision came a day after the New York state governor, Andrew Cuomo, said that the state’s health department would begin to treat critically ill patients with convalescent plasma. New York officials said they would recruit patients who have recovered from covid-19, probably from the New York City suburb

You will have to log in or register to view the full content.

Choose language »